Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib and Gemcitabine for Advanced Pancreatic Cancer
NCT00095966Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2004
- Primary completion
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in pancreatic adenocarcinoma (PDAC), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 6 months. Started Sep 2004; status: completed.
02
Drugs
sorafenib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00095966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00095966.